In contrast, Sakaguchi’s group analyzed 147 patients with FLT3-ITD gene mutation-positive AML, stratifying them, according to ELN indications, into high and low AR, depending on the presence or absence of the NPM1 mutation. The gene discussed is FLT3; the disease is acute myeloid leukemia.